{"id":"NCT00521586","sponsor":"Pfizer","briefTitle":"Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine","officialTitle":"A Phase 3, Randomized, Double-blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vpnc Administered 5 Years After Initial 13vpnc Vaccination","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2007-08-28","resultsPosted":"2015-04-09","lastUpdate":"2015-04-09"},"enrollment":1116,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"13 valent pneumococcal conjugate vaccine","otherNames":["0.5 mL dose of TIV and 13vPnC at dose 1, 0.5 mL dose of of placebo at dose 2, and 0.5ml dose of 13vPnC at year 5 will be administered into left deltoid muscle"]},{"type":"BIOLOGICAL","name":"13 valent pneumococcal conjugate vaccine","otherNames":["0.5 mL dose of TIV and of placebo at dose 1 and 0.5 mL dose of 13vPnC at dose 2 and year 5 will be administered into left deltoid muscle"]}],"arms":[{"label":"1","type":"OTHER"},{"label":"2","type":"OTHER"}],"summary":"This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years who are naive to 23-valent pneumococcal polysaccharide vaccine (23vPS), or when the vaccines are given 1 month apart. It will also evaluate the immune response to 13vPnC once per year for 4 years and then to a second dose of 13vPnC given 5 years after the first dose.","primaryOutcome":{"measure":"Percentage of Participants Achieving at Least 4-fold Increase in Titer for Concomitant Trivalent Inactivated Influenza Vaccine (TIV) Antigens 1 Month After Dose 1","timeFrame":"1 month after Dose 1","effectByArm":[{"arm":"13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)","deltaMin":84,"sd":null},{"arm":"Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)","deltaMin":81.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":41,"countries":["United States"]},"refs":{"pmids":["27155493","22739693"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6115A1-3001&StudyName=Study%20Evaluating%20%2013%20Valent%20Pneumococcal%20Conjugate%20Vaccine%20with%20Trivalent%20Inactivated%20Influenza%20Vaccine"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":551},"commonTop":["Any systemic event","Any local reaction","Pain: Any","Pain: Mild","Headache: any"]}}